BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Abbott Laboratories (ABT), Seattle Genetics, Inc. (SGEN) Sign Cancer Pact Worth $245 Million


10/23/2012 8:33:53 AM

Abbott Laboratories | Jobs at Abbott Laboratories
Seattle Genetics Inc. | Jobs at Seattle Genetics Inc.

Abbott Laboratories (ABT) will pay a $25 million upfront fee to Seattle Genetics Inc. (SGEN) for expanded rights to utilize Seattle Genetics' technology for cancer. The expanded collaboration between the two drug companies allows Abbott to gain rights to utilize Seattle Genetics' auristatin-based antibody-drug conjugate technology with antibodies to additional oncology targets. In addition, Seattle Genetics may receive up to $220 million in potential milestone payments per additional target upon achieving predetermined objectives, as well as mid-to-high single-digit royalties on worldwide net sales of any resulting products under the collaboration. "ADCs have emerged as an important therapeutic approach to cancer, driven by the FDA approval of Adcetris, and encouraging data from numerous clinical and preclinical ADC programs in development by Seattle Genetics and our collaborators," said Natasha Hernday, vice president of corporate development at Seattle Genetics. "This expanded collaboration with Abbott further validates our technology and approach in targeting and treating cancer." Antibody-drug conjugates are monoclonal antibodies that are designed to selectively deliver cytotoxic agents to tumor cells. Adcetris is the first drug approved utilizing Seattle Genetics' ADC technology.


Read at Nasdaq

Nasdaq
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES